title: Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.
abstract: Tamoxifen may require metabolic activation to endoxifen for efficacy in treating hormone receptor-positive breast cancer. Dose escalation in patients with low endoxifen concentrations could enhance treatment efficacy. This approach is clinically feasible, and successfully increases endoxifen concentrations; however, it is unknown whether patients benefit from individualized tamoxifen dose escalation. Clin Cancer Res; 22(13); 3121-3. ©2016 AACRSee related article by Fox et al., p. 3164.
authors.affiliation: Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan. DLHertz@med.umich.edu.
authors.forename: Daniel L
authors.initials: DL
authors.lastname: Hertz
authors.affiliation: Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
authors.forename: James M
authors.initials: JM
authors.lastname: Rae
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D054796:Drug Dosage Calculations; D005260:Female; D006801:Humans; D013629:Tamoxifen / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; C055492:4-hydroxy-N-desmethyltamoxifen